Please login to the form below
depression
This page shows the latest depression news and features for those working in and with pharma, biotech and healthcare.
Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3
Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies. ... These results represent hope and positive progress for the more than 250 million patients worldwide who are estimated to live with depression.
Latest news
-
bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
Seeing friends with thalassaemia die prematurely. Dealing with mental health issues and depression.
-
Biogen signs $3.1bn deal with Sage for potential depression therapies
Biogen has bet up to $3.1bn on a series of potential depression and movement disorder therapies currently being developed by Sage Therapeutics. ... Scale for Depression (HAM-D) total score at day 15 compared to placebo.
-
Acadia’s Nuplazid misses the mark in major depressive disorder trial
The drug failed to improve patient scores on the Hamilton Depression Rating Scale (HAMD-17) – a standard measure used for depression and the primary endpoint of the study. ... our earlier positive depression studies as we assess the next steps,” he
-
The best work in healthcare communications shines at virtual Communiqué Awards
6. Excellence in Multichannel Communications. Sponsored by Hanover. Winner: Breaking Depression – A Story of 40 Million Broken Pieces by Publicis Health for Janssen EMEA. ... Sponsored by Say Communications. Winner: Breaking Depression – A Story of
-
Trevena gets second go at FDA approval for pain drug
Some concluded there wasn’t enough data on side effects like respiratory depression compared to equivalent doses of current opioids such as morphine – even though oliceridine was specifically developed to reduce
bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
Biogen signs $3.1bn deal with Sage for potential depression therapies
Acadia’s Nuplazid misses the mark in major depressive disorder trial
The best work in healthcare communications shines at virtual Communiqué Awards
Trevena gets second go at FDA approval for pain drug
More from news
Approximately 28 fully matching, plus 301 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
They include: smoking, excessive alcohol consumption, diabetes, depression, hypertension, hearing impairment and mid-life obesity, in addition to a lack of social contact and physical exercise.
-
The impact of cancer on mental health during COVID-19
developing clinical levels of depression at some point in their journey.
-
Helping patients to help themselves – how pharma can get more from patient support programmes
For example, the Sanvello app () uses cognitive behavioural therapy to help patients relieve stress, anxiety and depression.
-
COVID-19 hits supply chains
During the Great Depression, this was called ‘yardstick capitalism’, Stoller noted, and it gives the government insight into proprietary data otherwise unobtainable.
-
Will biosimilars ever catch on in the US?
First-to-market generics included medicines for opioid overdose, pulmonary arterial hypertension, breast cancer, seizures, depression and various infections.
Alzheimer’s: the search for a cure
The impact of cancer on mental health during COVID-19
Helping patients to help themselves – how pharma can get more from patient support programmes
COVID-19 hits supply chains
Will biosimilars ever catch on in the US?
More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.
Latest appointments
-
Clark Health Communications expands team
director in a role that will see her lead teams responsible for driving the delivery of CHC’s gastroenterology, women’s health, depression and anticoagulants business.
-
Dr Niall Murphy and Pierre Schwich join Pharnext
Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity
-
Turing names Eliseo Salinas as head of R&D
Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,
-
Lundbeck promotes Andreas Eggert and Klaus Abel to senior commercial roles
vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence. ... including a once-monthly aripiprazole formulation for the treatment of schizophrenia and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major
Clark Health Communications expands team
Dr Niall Murphy and Pierre Schwich join Pharnext
Turing names Eliseo Salinas as head of R&D
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Clinical trial branding: 5 reasons it’s important to your clinical trials
Imagine the branding you’d use to target an audience for an arthritis clinical trial, how would that differ to the branding used for a depression clinical trial?
-
Feeling the pressure?
2. Three quarters cited comms agencies as the most stressful sector and 20% take sick leave due to anxiety, depression or stress. ... The CIPR’s State of the Profession report found 23% of people take sick leave due to stress, anxiety and depression
-
Next Generation Consultancy Launches To Help Creative Agency Teams Manage The Pressures Of Agency Life
on the grounds of stress, anxiety or depression.
-
WHITE PAPER: What's missing in women's health?
Changes to the mind and body can mean that women no longer feel ‘like themselves’ alongside experiencing debilitating brain fog and even spells of depression. ... Menopause, Depression and Anxiety: Dr Louise Newson. Menopause Doctor.
-
Can cultural safety training for sites improve diversity?
They complain about back pain, stomach pain, but they are describing anxiety or depression.
Clinical trial branding: 5 reasons it’s important to your clinical trials
Next Generation Consultancy Launches To Help Creative Agency Teams Manage The Pressures Of Agency Life
WHITE PAPER: What's missing in women's health?
Can cultural safety training for sites improve diversity?
More from PMHub
Approximately 5 fully matching, plus 39 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Salary TBC
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
-
Planner
-
Salary TBC
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Sanofi’s C1s inhibitor sutimlimab hits the mark in late-stage CAD study
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- US announces $3bn funding boost for antiviral COVID-19 treatments
- Biogen doses first patient in phase 3 systemic lupus erythematosus study
- Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
- ‘Funny’, ha ha: how neurodiverse comedy can help us understand each other
- BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Sanofi, GSK begin enrolment for phase 3 COVID-19 vaccine study
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Sense of belonging
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- How early-stage clinical research is facilitating the new wave of personalised medicines
- By Jorg Taubel...
- Patient diversity in clinical trials needs to be centre stage
- By Danny Buckland...
- Why empathy in digital patient recruitment is vital
- This is where empathy mapping can be incredibly effective....
